Loading organizations...
§ Private Profile · Tokyo, Tokyo, Japan
Regenerative medicine startup developing iPS cell therapies for bullous keratopathy, addressing corneal donor shortages.
Founded in January 2015 by Keio University professors Shin Hatou, Kazuo Tsubota, and Shigeto Shimmura, Cellusion is a Tokyo-based regenerative medicine startup developing cell therapies for bullous keratopathy. The company utilizes a proprietary differentiation method to create injectable iPS cell-derived corneal endothelial cell substitutes, known as CLS001, addressing severe donor shortages for corneal transplants. To advance clinical trials, the venture raised over one billion JPY in Series A financing during January 2022 and formed strategic alliances with Toho Holdings, Minaris Regenerative Medicine, and Fosun Pharma subsidiary Celregen. In 2024, the enterprise received United States FDA Orphan Drug Designation for its lead candidate and relocated its headquarters to Harumi, Chuo-ku, establishing a dedicated laboratory. Furthermore, the organization was selected for the AMED Strengthening Program for Pharmaceutical Startup Ecosystem in December 2023 to support its ongoing research.
Cellusion has raised $29.8M across 2 funding rounds.
Cellusion has raised $29.8M in total across 2 funding rounds.
Cellusion has raised $29.8M in total across 2 funding rounds.
Cellusion's investors include AIS CAPITAL, Axil Capital, DBJ Capital, Gemseki, Yoshiharu Asai, Nikon-SBI Innovation Fund, Junichi Imoto, SMBC Venture Capital, SPARX Asset Management, Hiroaki Kobayashi, Keio Innovation Initiative, Toho Holding.
Cellusion has raised $29.8M across 2 funding rounds. Most recently, it raised $20.3M Series C in June 2023.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jun 7, 2023 | $20.3M Series C | — | AIS Capital, Axil Capital, DBJ Capital, Gemseki, Yoshiharu Asai, Nikon SBI Innovation Fund, Junichi Imoto, SMBC Venture Capital, Sparx Asset Management, Hiroaki Kobayashi | Announced |
| Jan 7, 2022 | $9.5M Venture Round | DBJ Capital, Keio Innovation Initiative, SMBC Venture Capital | Gemseki, Toho Holding, Toyo Seikan, University OF Tokyo Edge Capital | Announced |